vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and MITEK SYSTEMS INC (MITK). Click either name above to swap in a different company.

MITEK SYSTEMS INC is the larger business by last-quarter revenue ($44.2M vs $38.3M, roughly 1.2× ImmunityBio, Inc.). MITEK SYSTEMS INC runs the higher net margin — 6.3% vs -161.8%, a 168.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 18.8%). MITEK SYSTEMS INC produced more free cash flow last quarter ($6.6M vs $-71.3M).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Mitek Systems, Inc. is a software company that specializes in digital identity verification and mobile image processing using artificial intelligence. The company's software is used for depositing checks and opening bank accounts via mobile devices. It also verifies identity documents such as passports, ID cards, and driver's licenses by analyzing a selfie of an individual holding their ID, comparing their face to the photo on the document.

IBRX vs MITK — Head-to-Head

Bigger by revenue
MITK
MITK
1.2× larger
MITK
$44.2M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+388.2% gap
IBRX
407.0%
18.8%
MITK
Higher net margin
MITK
MITK
168.1% more per $
MITK
6.3%
-161.8%
IBRX
More free cash flow
MITK
MITK
$77.9M more FCF
MITK
$6.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
MITK
MITK
Revenue
$38.3M
$44.2M
Net Profit
$-61.9M
$2.8M
Gross Margin
99.0%
Operating Margin
-169.0%
12.3%
Net Margin
-161.8%
6.3%
Revenue YoY
407.0%
18.8%
Net Profit YoY
-4.7%
160.1%
EPS (diluted)
$-0.06
$0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
MITK
MITK
Q4 25
$38.3M
$44.2M
Q3 25
$32.1M
$44.8M
Q2 25
$26.4M
$45.7M
Q1 25
$16.5M
$51.9M
Q4 24
$7.6M
$37.3M
Q3 24
$6.1M
$43.2M
Q2 24
$45.0M
Q1 24
$47.0M
Net Profit
IBRX
IBRX
MITK
MITK
Q4 25
$-61.9M
$2.8M
Q3 25
$-67.3M
$1.9M
Q2 25
$-92.6M
$2.4M
Q1 25
$-129.6M
$9.2M
Q4 24
$-59.2M
$-4.6M
Q3 24
$-85.7M
$8.6M
Q2 24
$216.0K
Q1 24
$282.0K
Gross Margin
IBRX
IBRX
MITK
MITK
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
MITK
MITK
Q4 25
-169.0%
12.3%
Q3 25
-173.5%
10.5%
Q2 25
-269.8%
8.3%
Q1 25
-390.1%
21.9%
Q4 24
-919.0%
-8.3%
Q3 24
-1314.3%
17.8%
Q2 24
1.6%
Q1 24
1.5%
Net Margin
IBRX
IBRX
MITK
MITK
Q4 25
-161.8%
6.3%
Q3 25
-209.8%
4.2%
Q2 25
-350.3%
5.2%
Q1 25
-784.9%
17.6%
Q4 24
-783.4%
-12.4%
Q3 24
-1404.0%
19.8%
Q2 24
0.5%
Q1 24
0.6%
EPS (diluted)
IBRX
IBRX
MITK
MITK
Q4 25
$-0.06
$0.06
Q3 25
$-0.07
$0.04
Q2 25
$-0.10
$0.05
Q1 25
$-0.15
$0.20
Q4 24
$-0.08
$-0.10
Q3 24
$-0.14
$0.19
Q2 24
$0.00
Q1 24
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
MITK
MITK
Cash + ST InvestmentsLiquidity on hand
$242.8M
$190.1M
Total DebtLower is stronger
$4.8M
Stockholders' EquityBook value
$-500.5M
$233.7M
Total Assets
$501.9M
$446.5M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
MITK
MITK
Q4 25
$242.8M
$190.1M
Q3 25
$257.8M
$193.0M
Q2 25
$153.7M
$167.1M
Q1 25
$61.6M
$136.2M
Q4 24
$149.8M
$121.2M
Q3 24
$130.4M
$130.3M
Q2 24
$123.1M
Q1 24
$123.9M
Total Debt
IBRX
IBRX
MITK
MITK
Q4 25
$4.8M
Q3 25
$4.3M
Q2 25
Q1 25
Q4 24
Q3 24
$2.7M
Q2 24
Q1 24
Stockholders' Equity
IBRX
IBRX
MITK
MITK
Q4 25
$-500.5M
$233.7M
Q3 25
$-524.3M
$240.3M
Q2 25
$-570.7M
$237.6M
Q1 25
$-591.4M
$220.2M
Q4 24
$-489.1M
$200.9M
Q3 24
$-745.1M
$214.8M
Q2 24
$209.6M
Q1 24
$216.1M
Total Assets
IBRX
IBRX
MITK
MITK
Q4 25
$501.9M
$446.5M
Q3 25
$519.0M
$459.1M
Q2 25
$402.1M
$446.7M
Q1 25
$303.8M
$425.3M
Q4 24
$382.9M
$396.0M
Q3 24
$364.6M
$413.8M
Q2 24
$409.2M
Q1 24
$417.0M
Debt / Equity
IBRX
IBRX
MITK
MITK
Q4 25
0.02×
Q3 25
0.02×
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
MITK
MITK
Operating Cash FlowLast quarter
$-70.4M
$8.0M
Free Cash FlowOCF − Capex
$-71.3M
$6.6M
FCF MarginFCF / Revenue
-186.2%
14.9%
Capex IntensityCapex / Revenue
2.4%
3.2%
Cash ConversionOCF / Net Profit
2.89×
TTM Free Cash FlowTrailing 4 quarters
$-308.8M
$60.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
MITK
MITK
Q4 25
$-70.4M
$8.0M
Q3 25
$-68.9M
$19.5M
Q2 25
$-79.7M
$21.6M
Q1 25
$-85.9M
$13.7M
Q4 24
$-85.1M
$565.0K
Q3 24
$-98.8M
$21.1M
Q2 24
$13.0M
Q1 24
$7.1M
Free Cash Flow
IBRX
IBRX
MITK
MITK
Q4 25
$-71.3M
$6.6M
Q3 25
$-69.6M
$19.2M
Q2 25
$-80.8M
$21.2M
Q1 25
$-87.0M
$13.5M
Q4 24
$-87.3M
$230.0K
Q3 24
$-101.6M
$20.8M
Q2 24
$12.6M
Q1 24
$6.6M
FCF Margin
IBRX
IBRX
MITK
MITK
Q4 25
-186.2%
14.9%
Q3 25
-217.2%
42.9%
Q2 25
-305.9%
46.5%
Q1 25
-526.9%
26.0%
Q4 24
-1155.4%
0.6%
Q3 24
-1663.2%
48.2%
Q2 24
27.9%
Q1 24
14.0%
Capex Intensity
IBRX
IBRX
MITK
MITK
Q4 25
2.4%
3.2%
Q3 25
2.3%
0.6%
Q2 25
4.1%
0.7%
Q1 25
6.8%
0.4%
Q4 24
28.0%
0.9%
Q3 24
45.7%
0.7%
Q2 24
1.0%
Q1 24
1.0%
Cash Conversion
IBRX
IBRX
MITK
MITK
Q4 25
2.89×
Q3 25
10.46×
Q2 25
9.00×
Q1 25
1.50×
Q4 24
Q3 24
2.46×
Q2 24
60.12×
Q1 24
25.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

MITK
MITK

Fraud And Identity Solutions$25.5M58%
License$13.9M31%
Fraud And Identity Solutions Software License And Support$3.9M9%
Professional Services And Other$1.2M3%

Related Comparisons